---

USA FACILITIES

CHINA FACILITIES

Our Gaithersbug integrated molecular diagnostics laboratory is located in suburban Washington, DC, in Maryland, close to the National Institutes of Health (NIH), one of the world's leading centers for biological research. Our proximity to and interaction with NIH, along with spirited connections with our other strategic partners in the academic, biotechnology and clinical communities enables us to stay at the forefront of diagnostic medicine and closely monitor trends and developments in molecular cytogenetics. It also allows us to take a uniquely proactive approach to the development and validation of tests in response to new and anticipated needs of research and clinical pathology. In addition to housing our cutting edge technology development programs, the laboratory offers advanced genomics-based diagnostic, prognostic and screening services for all aspects of precision medicine, ranging from genetic aberration testing, early, accurate and non-invasive cancer diagnosis and prediction of drug sensitivity or resistance to guiding personalized treatment strategies.
Services:    
-- Fluorescence in situ Hybridization: full-service molecular cytogenetics testing, predominantly for oncology and  prenatal medicine applications
 -- Microarray and qPCR Gene Expression and mutation detection services
-- Sequencing services, including whole genome and exome analyses, comprehensive as well as targeted disease-specific panels, and a full range of next-generation sequencing (NGS) analytics solutions.

Our Beijing development and testing facility harbors a state-of-the-art LDT-laboratory offering a full range of modern molecular diagnostics services, for both clinical and research needs. Services offered range from standard clinical diagnostic processes to novel genomic and precision medicine methods, including versatile microarray platform testing, a full scope of sequencing services (whole genome and exome analyses, sequencing panels, NGS analytics solutions), and the most up-to-date techniques for cytogenetic examination, particularly expert Fluorescence in situ Hybridization (FISH) approaches, for genetic testing, cancer diagnosis and as companion diagnostics for personalized medicine and treatment guidance. Examples of common personalized medicine tests in contemporary oncology are ERBB2 amplification determination for breast and stomach cancer, ALK translocation as well as ALK-EML4 fusion testing in lung cancer, early detection of TERC/3q copy number increases for prediction of aggressive cervical tumors, and BCR-ABL1 fusion detection in chronic leukemias. Many novel genomic aberration tests for early recognition of disease and selection of optimal therapeutic strategies are in various stages of development and regulatory approval today.
It is predicted that China will perform over 300 Million molecular diagnostic tests during the forecasting period 2015 - 2019. Our fully integrated laboratories enable physicians, researchers, pathologists, and clinical and government laboratories, to incorporate the wealth of established as well as novel complex molecular tests into clinical practice.